2025年4月15日,映恩生物(Duality Biotherapeutics Inc, 09606.HK)成功完成香港首次公开发行,此次上市募集资金规模绿鞋前约为2.11亿美元,绿鞋后约达2.42亿美元。摩根士丹利1在本次项目中担任牵头保荐人、牵头全球协调人及牵头账簿管理人。映恩生物是一家临床阶段的创新生物科技企业,专注于为癌症和自身免疫性疾病患者研发新一代抗体偶联药物(antibody-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.